Research programme: inflammation therapy - Kowa/Pharmacopeia Drug Discovery
Latest Information Update: 17 May 2006
At a glance
- Originator Kowa; Pharmacopeia Drug Discovery
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 17 May 2006 No development reported - Preclinical for Inflammation in Japan (unspecified route)
- 17 May 2006 No development reported - Preclinical for Inflammation in USA (unspecified route)
- 06 May 2004 Pharmacopeia has divided into Pharmacopeia Drug Discovery and Accelrys